Clinical Context
A pediatric or young adult patient with genetically confirmed Duchenne muscular dystrophy (DMD) presents to an outpatient infusion center for scheduled treatment with the antisense oligonucleotide therapy viltolarsen. The medication is supplied as J1427 (injection, viltolarsen, 10 mg) and is administered via intravenous infusion or as prescribed by the manufacturer in a controlled clinical setting. The clinical workflow includes: pre-infusion assessment (weight, vital signs, review of laboratory tests including liver function and renal function), verification of diagnosis and prior authorization, medication preparation by pharmacy (dose calculation based on weight and vial count of J1427), placement of an IV line, infusion under nursing observation, monitoring for infusion-related reactions and adverse effects, post-infusion observation for a specified period, documentation of lot number and vial wastage, and billing using the J1427 HCPCS Level II code with appropriate modifiers and diagnosis linkage. Typical sites of service are outpatient infusion centers, hospital outpatient departments, or specialty ambulatory clinics. A typical patient scenario: a 9-year-old male with confirmed DMD receiving routine monthly infusion of viltolarsen with prior authorization approved by Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, or Medicare; nursing documents vitals and infusion tolerance, pharmacy documents vial lot and any discarded drug using modifier JW if applicable, and the billing office submits J1427 with the diagnosis and any applicable modifiers.